Skip to content

Aripiprazole Augmentation of SSRI Therapy in Treatment Refractory Depression

Aripiprazole Augmentation of SSRI Antidepressant Therapy in Treatment Refractory Depression: Assessment of Symptom Reduction, Psychosocial Function, and Cognitive Function

Status
Completed
Phases
Phase 4
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00608543
Enrollment
17
Registered
2008-02-06
Start date
2005-10-31
Completion date
2009-01-31
Last updated
2012-10-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Major Depressive Disorder

Keywords

cognitive function, psychosocial function, augmentation, treatment refractory depression

Brief summary

Our target population will have been adequately treated with one of three selective serotonin reuptake inhibitors (SSRIs; escitalopram, citalopram, or sertraline) for at least 8-12 weeks and continue to experience symptoms of depression that have prompted them to seek additional treatment. Escitalopram, citalopram, and sertraline were selected for use in this study because they are among the most commonly selected SSRIs and they are associated with a reduced likelihood of drug-drug interactions with aripiprazole. After completion of the screening process, eligible participants will be augmented with aripiprazole (5, 10, or 15 mg) for 6 weeks. Participants will continue SSRI treatment with their prescribing physician, in conjunction with study participation. Symptom severity will be assessed on a weekly basis, and cognitive and psychosocial function will be assessed at pre- and post-augmentation. We hypothesize that aripiprazole augmentation will be associated with reductions in symptom severity, and with improved performance on measures of psychosocial and cognitive function.

Interventions

DRUGAripiprazole

varied dose (5, 10, 15 mg qd) for 6 wks

Sponsors

Bristol-Myers Squibb
CollaboratorINDUSTRY
University of Texas Southwestern Medical Center
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
No

Inclusion criteria

* Age 18-65 * Primary diagnosis of Major Depressive Disorder (MDD) * Completion of at least 8-12 weeks (and no longer than 6 months) of treatment with escitalopram, citalopram, or sertraline, with at least 6 weeks at an adequate dose (i.e., 20 mg escitalopram; 40 mg citalopram; 150 mg sertraline) * Hamilton Rating Scale for Depression, 17-item (HRSD17) score less than or equal to 14 and/or Clinical Global Impression - Severity (CGI-S) score less than or equal to 3 * Self-reported difficulties with cognition and/or concentration, and an Inventory for Depressive Symptomatology Clinician-Rated, 30-item (IDS-C30) item #16 (Concentration and Decision Making) score less than or equal to 2 * Ability to read and write in English (required because instructions for cognitive testing and several questionnaires are available only in English)

Exclusion criteria

* Presence of untreated or unstable comorbid medical condition based on physician information or evidence at examination, such as hypertension, diabetes, hypothyroidism. * Presence of known cardiovascular disease or seizure disorder. * Presence of other primary psychiatric disorders or conditions (including depression due to medical conditions, currently suicidal or high suicide risk, current or past psychotic disorders of any type, bipolar disorder (I, II, or Not Otherwise Specified \[NOS\]), schizophrenia, schizoaffective disorder, anorexia, bulimia, obsessive compulsive disorder, alcohol or substance abuse or dependence within the last 6 months) * Presence of organic brain injury or dementia, based on a cutoff score of \< 20 on the Mini Mental Status Examination (MMSE). * Concomitant pharmacological or psychotherapeutic treatment (in addition to one SSRI as described in Inclusion Criteria) including but not limited to anxiolytics, neuroleptics, mood stabilizers * Hospitalization for mental illness within the past year. * For women, currently pregnant or planning to become pregnant in the next year.

Design outcomes

Primary

MeasureTime frameDescription
Stockings of Cambridge (SOC) Mean Initial Thinking Time for 3-move Problemsbaseline and 6 weeksThe SOC is part of the CAmbridge Neuropsychological Test Automated Battery (CANTAB) and is an executive function task based on the Tower of London test that assesses spatial planning for problems with 2, 3, 4, or 5 moves. The Mean Initial Thinking Time for 3-move problems is the time (in milliseconds)taken to plan a problem solution for trials requiring 3 moves. Higher numbers indicate poorer performance. Time reported is the difference between baseline and 6 weeks post-treatment.
Stockings of Cambridge (SOC) Mean Initial Thinking Time for 5-move Problemsbaseline and 6 weeksThe SOC is part of the CAmbridge Neuropsychological Test Automated Battery (CANTAB) and is an executive function task based on the Tower of London test that assesses spatial planning for problems with 2, 3, 4, or 5 moves. The Mean Initial Thinking Time for 5-move problems is the time (in milliseconds) taken to plan a problem solution for trials requiring 5 moves. Higher numbers indicate poorer performance. Time reported is the difference between baseline and 6 weeks post-treatment.
Spatial Working Memory (SWM) Between Errors for 6-move Problemsbaseline and 6 weeksThe SWM task is part of the CANTAB neruopsychological test battery and is an executive function task assessing retention and manipulation of items in working memory, with the ability for assessment of perseverative (redundant) errors. Between errors are times the subject revisits a box in which a token was previously found; errors are calculated for 4-, 6-, and 8-box trials. Higher numbers indicate poorer performance. Errors reported are the difference between baseline and 6 weeks post-treatment.
Spatial Working Memory (SWM) Strategy Scorebaseline and 6 weeksThe SWM task is part of the CANTAB neruopsychological test battery and is an executive function task assessing retention and manipulation of items in working memory, with the ability for assessment of perseverative (redundant) errors. The Strategy score represents the number of times a participant begins a search with the same box for 6- and 8-box problems. Minimum score is 8 and maximum score is 56. Higher numbers indicate poorer performance. Score reported is the difference between baseline and 6 weeks post-treatment.

Secondary

MeasureTime frameDescription
Quality of Life Enjoyment and Satisfaction Questionnaire6 weeksThe Q-LES-Q general activities is designed to measure subjective satisfaction and enjoyment, as opposed to function, in various domains including physical health, feelings, work, household duties, school/course work, leisure time activities, social relations, and general activities. The raw score is converted into a percent of the maximum possible score and range from 0 to 100. Higher scores indicate greater enjoyment and satisfaction.
Change in Hamilton Rating Scale for Depression (HRSD - 17-item)6 weeksThe HRSD 17-item scale is a clinician-administered rating scale designed to assess the severity of symptoms in patients diagnosed with depression. Scores range from 0 to 52, with higher scores indicating higher levels of depression severity.

Countries

United States

Participant flow

Participants by arm

ArmCount
Open-label Aripiprazole Augmentation
Aripiprazole augmentation of existing escitalopram, citalopram, or sertraline treatment was provided to study participants at a flexible dose between 5-15 mg (based on clinical symptoms and side effects) for 6 weeks
17
Total17

Withdrawals & dropouts

PeriodReasonFG000
Overall StudyAdverse Event4

Baseline characteristics

CharacteristicOpen-label Aripiprazole Augmentation
Age, Categorical
<=18 years
0 Participants
Age, Categorical
>=65 years
0 Participants
Age, Categorical
Between 18 and 65 years
17 Participants
Age Continuous48.18 years
STANDARD_DEVIATION 7.95
Region of Enrollment
United States
17 participants
Sex: Female, Male
Female
13 Participants
Sex: Female, Male
Male
4 Participants

Adverse events

Event typeEG000
affected / at risk
deaths
Total, all-cause mortality
— / —
other
Total, other adverse events
14 / 17
serious
Total, serious adverse events
0 / 17

Outcome results

Primary

Spatial Working Memory (SWM) Between Errors for 6-move Problems

The SWM task is part of the CANTAB neruopsychological test battery and is an executive function task assessing retention and manipulation of items in working memory, with the ability for assessment of perseverative (redundant) errors. Between errors are times the subject revisits a box in which a token was previously found; errors are calculated for 4-, 6-, and 8-box trials. Higher numbers indicate poorer performance. Errors reported are the difference between baseline and 6 weeks post-treatment.

Time frame: baseline and 6 weeks

Population: Completers because data were collected pre- and post-treatment

ArmMeasureValue (MEAN)Dispersion
Open Label Aripiprazole AugmentationSpatial Working Memory (SWM) Between Errors for 6-move Problems-4.00 number of errorsStandard Deviation 4.67
Primary

Spatial Working Memory (SWM) Strategy Score

The SWM task is part of the CANTAB neruopsychological test battery and is an executive function task assessing retention and manipulation of items in working memory, with the ability for assessment of perseverative (redundant) errors. The Strategy score represents the number of times a participant begins a search with the same box for 6- and 8-box problems. Minimum score is 8 and maximum score is 56. Higher numbers indicate poorer performance. Score reported is the difference between baseline and 6 weeks post-treatment.

Time frame: baseline and 6 weeks

Population: Completers; due to fact that testing occurred at pre- and post-intervention; mean represents difference between pre- and post-intervention

ArmMeasureValue (MEAN)Dispersion
Open Label Aripiprazole AugmentationSpatial Working Memory (SWM) Strategy Score-3.15 units on a scaleStandard Deviation 4.52
Primary

Stockings of Cambridge (SOC) Mean Initial Thinking Time for 3-move Problems

The SOC is part of the CAmbridge Neuropsychological Test Automated Battery (CANTAB) and is an executive function task based on the Tower of London test that assesses spatial planning for problems with 2, 3, 4, or 5 moves. The Mean Initial Thinking Time for 3-move problems is the time (in milliseconds)taken to plan a problem solution for trials requiring 3 moves. Higher numbers indicate poorer performance. Time reported is the difference between baseline and 6 weeks post-treatment.

Time frame: baseline and 6 weeks

Population: Completers; due to fact that testing occurred at pre- and post-intervention; mean represents difference between pre- and post-intervention

ArmMeasureValue (MEAN)Dispersion
Open Label Aripiprazole AugmentationStockings of Cambridge (SOC) Mean Initial Thinking Time for 3-move Problems-4485.50 millisecondsStandard Deviation 6279.4
Primary

Stockings of Cambridge (SOC) Mean Initial Thinking Time for 5-move Problems

The SOC is part of the CAmbridge Neuropsychological Test Automated Battery (CANTAB) and is an executive function task based on the Tower of London test that assesses spatial planning for problems with 2, 3, 4, or 5 moves. The Mean Initial Thinking Time for 5-move problems is the time (in milliseconds) taken to plan a problem solution for trials requiring 5 moves. Higher numbers indicate poorer performance. Time reported is the difference between baseline and 6 weeks post-treatment.

Time frame: baseline and 6 weeks

Population: Completers; due to fact that testing occurred at pre- and post-intervention; mean represents difference between pre- and post-intervention

ArmMeasureValue (MEAN)Dispersion
Open Label Aripiprazole AugmentationStockings of Cambridge (SOC) Mean Initial Thinking Time for 5-move Problems-4676.10 millisecondsStandard Deviation 8604.16
Secondary

Change in Hamilton Rating Scale for Depression (HRSD - 17-item)

The HRSD 17-item scale is a clinician-administered rating scale designed to assess the severity of symptoms in patients diagnosed with depression. Scores range from 0 to 52, with higher scores indicating higher levels of depression severity.

Time frame: 6 weeks

Population: Study completers who completed the HRSD pre- and post-intervention; mean represents mean difference from pre- to post-intervention

ArmMeasureValue (MEAN)Dispersion
Open Label Aripiprazole AugmentationChange in Hamilton Rating Scale for Depression (HRSD - 17-item)-11.42 units on a scaleStandard Deviation 4.5
Secondary

Quality of Life Enjoyment and Satisfaction Questionnaire

The Q-LES-Q general activities is designed to measure subjective satisfaction and enjoyment, as opposed to function, in various domains including physical health, feelings, work, household duties, school/course work, leisure time activities, social relations, and general activities. The raw score is converted into a percent of the maximum possible score and range from 0 to 100. Higher scores indicate greater enjoyment and satisfaction.

Time frame: 6 weeks

Population: Study completers who completed the Q-LES-Q pre- and post-intervention; mean represents mean difference from pre- to post-intervention

ArmMeasureValue (MEAN)Dispersion
Open Label Aripiprazole AugmentationQuality of Life Enjoyment and Satisfaction Questionnaire0.81 units on a scaleStandard Deviation 0.48

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026